Citi Pharma is an API-led pharmaceutical manufacturer moving further into finished formulations. That combination can improve margins, but it also creates a working-capital cycle: raw materials must be bought, processed and stocked before customers pay. For the nine months ended March 31, 2026, sales, profit and gross margin rose while receivables, inventory, borrowing and negative operating cash flow exposed funding costs. The business is best read through product mix and cash conversion together.
Company Name: Citi Pharma Ltd
Ticker: CPHL
What Citi Pharma does
The company’s legal name in public filings is Citi Pharma Limited. It was incorporated in Pakistan on October 8, 2012 as a private company, converted to a public unlisted company in October 2020 and began trading on the Pakistan Stock Exchange in July 2021. Its registered manufacturing base is at 3-KM Head Balloki Road, Bhai Pheru, District Kasur. The stated principal activity is the manufacture and sale of pharmaceuticals, medical chemicals and botanical products. Pakistan Stock Exchange company profile.
In practice, Citi Pharma sits at two adjacent points in the pharmaceutical value chain. It manufactures active pharmaceutical ingredients, or APIs—the chemically active substances used by drug makers—and it produces finished formulations such as tablets, capsules, suspensions, sachets and injectables. The official product catalogue includes analgesic, antibiotic, gastrointestinal, respiratory and nutritional products, among others. This makes the company partly a business-to-business supplier to other pharmaceutical manufacturers and partly a producer of finished medicines sold through pharmaceutical distribution channels. Official formulations catalogue.
Citi Pharma reports only one accounting segment, but its economic mix is observable. In FY2025, APIs generated 76.4% of revenue and formulations 23.6%, compared with 83% and 17% a year earlier. Local sales were Rs12.80 billion and exports Rs364 million. The rising formulation share matters because finished products usually combine the active ingredient with dosage design, quality assurance, packaging, registration and distribution; they can therefore capture more of the value chain than bulk ingredient sales, although selling costs and receivable risk are also higher. FY2025 audited annual report.
Key facts and figures
- Corporate history: incorporated October 8, 2012; converted to a public unlisted company October 13, 2020; listed on PSX July 9, 2021. PSX profile.
- FY2025 net sales: Rs13.15 billion, up 6.0% from Rs12.41 billion in FY2024. Audited results.
- FY2025 gross profit: Rs2.02 billion; gross margin was 15.3%, up from 12.8%. Audited profit or loss statement.
- FY2025 profit after tax: Rs892.0 million, up 7.0%; EPS was Rs3.90. Audited results.
- FY2025 revenue mix: APIs 76.4% and formulations 23.6%, versus 83% and 17% in FY2024. Operating-segment note.
- FY2025 geographic mix: Rs12.80 billion of local sales and Rs364 million of exports. Operating-segment note.
- FY2025 year-end employees: 627, including 96 temporary employees. Employee note.
- Nine-month FY2026 sales: Rs10.79 billion, up 6.8% from Rs10.10 billion. March 2026 interim report.
- Nine-month FY2026 gross profit: Rs2.00 billion, up 37.3%; gross margin expanded to 18.5% from 14.4%. March 2026 interim report.
- Nine-month FY2026 profit after tax: Rs883.4 million, up 30.1%; EPS was Rs3.87. March 2026 interim report.
- March 2026 working capital: inventory Rs4.41 billion and trade debts Rs4.22 billion, both higher than at June 2025. Interim balance sheet.
- Nine-month FY2026 operating cash flow: negative Rs972.8 million despite Rs883.4 million of reported profit. Interim cash-flow statement.
- Issued shares at March 2026: 228.46 million ordinary shares of Rs10 each. Interim share-capital note.
How the business model works
The API engine
An API business starts with chemical inputs, validated processes and regulatory-quality production. Value comes from producing a consistent ingredient at the required purity and specification, at a cost that competes with imports. Citi Pharma’s disclosed API portfolio includes widely used molecules such as paracetamol, amoxicillin, levofloxacin, cefixime, ciprofloxacin, aspirin, ibuprofen and ascorbic acid. Demand can be relatively broad because these ingredients feed multiple branded and generic medicines, but individual API prices are exposed to imported feedstock costs, freight, exchange rates, global supply and customer purchasing cycles. FY2025 annual report.
The production process is capital- and quality-intensive. Chemical raw materials move through reaction, separation, drying, milling, testing and controlled packing before release. Different molecules use different equipment and cycle times, which is why the company says a single plant-capacity figure cannot be determined reliably for its multi-product facility. In FY2025, raw material consumed was Rs10.35 billion—by far the largest disclosed production cost—while wages were Rs386 million, packing material Rs242 million, wood or corn cube fuel Rs189 million and electricity Rs172 million. This cost structure explains why procurement, yields, batch efficiency, energy and foreign exchange can move gross margin materially. Cost-of-sales note.
Formulations move the company downstream
Finished formulations add dose design, excipients, manufacturing, stability work, packaging, registration and distribution to the API. Citi Pharma’s catalogue spans tablets, capsules, oral suspensions, drops, sachets and injectable products. A broader formulation portfolio can deepen relationships with distributors and prescribers, improve factory utilization and capture more margin per unit of API. It also requires marketing expenditure, product registrations, inventory by SKU and credit extended through the channel. The nine-month FY2026 accounts show this balance: management attributed stronger gross profit partly to a higher formulation contribution, while selling expense rose 49% to Rs178 million. March 2026 directors’ report and accounts.
The company’s strategic pipeline extends beyond conventional generics. Management says it is prioritizing biotech formulation, a penicillin project, export readiness and veterinary formulations through a wholly owned subsidiary. The veterinary operation has begun through outsourced manufacturing while a dedicated plant is planned. These are management statements about projects and intent, not yet proof of recurring earnings. Readers should look for registrations, commissioning, commercial volumes and segment-level economics before treating them as established profit engines. March 2026 directors’ report.
Customers, pricing and route to market
API customers are other pharmaceutical manufacturers that require approved inputs and reliable supply; formulation customers are reached through the medicine-distribution chain and institutional or export channels. Revenue is recognized when products are delivered, while exports are recognized when the bill of lading is issued. That accounting point matters because profit can be booked before cash is collected. The company’s FY2025 receivables rose 40% to Rs3.08 billion, then reached Rs4.22 billion by March 2026. Growth that lengthens collection time can consume more cash than it creates in near-term accounting profit. Revenue policy and receivables notes.
Pricing power is uneven. APIs compete with imported alternatives and global commodity-like supply, while finished medicines are affected by product registration and Pakistan’s drug-pricing framework. Management identifies regulated prices for essential medicines, exchange-rate movements, API and freight volatility, and supply-chain disruption as principal industry pressures. A favourable environment combines stable input availability, a firm rupee, lower financing costs, price adjustments that reflect costs and a richer formulation mix. The adverse case is the reverse: imported inputs rise faster than permitted selling prices while inventory and receivable days lengthen. March 2026 risk discussion.
The earnings engine: mix, margins and non-operating support
FY2025 showed the first part of the margin story. Sales rose 6.0% to Rs13.15 billion, but cost of sales increased only 2.9%, lifting gross profit 27.2% to Rs2.02 billion and gross margin to 15.3% from 12.8%. Operating profit increased 33.1% to Rs1.60 billion. Net profit grew a slower 7.0% to Rs892 million because finance cost rose and other income fell from Rs490 million to Rs198 million. That distinction is important: the underlying production-and-selling engine improved more than the bottom line, while interest and lower investment-related income absorbed part of the gain. FY2025 audited financial statements.
The first nine months of FY2026 extended the operating improvement. Sales rose 6.8% to Rs10.79 billion, gross profit advanced 37.3% to Rs2.00 billion and operating profit increased 40.9% to Rs1.65 billion. Gross margin reached 18.5%, about 4.1 percentage points above the comparable period. Management attributes this to cost controls, production efficiency, improved product mix and a higher contribution from formulations. Profit after tax rose 30.1% to Rs883 million despite finance cost increasing 21.8% and other income falling 52.1%. Official March 2026 interim filing.
The quarter alone was more mixed and prevents a straight-line growth reading. March-quarter sales fell 7.7% year on year to Rs3.08 billion, yet gross profit rose 6.9% to Rs523 million and profit after tax rose 25.0% to Rs275 million. Gross margin improved to 16.9% from 14.6%. AlphaGen inference: the current earnings improvement is more about unit economics and mix than rapid top-line expansion. Its durability depends on keeping formulations’ contribution and production efficiency high without allowing selling costs, finance charges or credit losses to catch up. Quarterly comparison in the interim accounts.
Balance sheet and cash conversion
Citi Pharma’s main financial constraint is the amount of cash tied up between procurement and collection. At March 31, 2026, stock-in-trade was Rs4.41 billion, 12.1% above June 2025, while trade debts were Rs4.22 billion, up 37.0%. Advances and other receivables also rose. By contrast, trade and other payables fell to Rs3.60 billion from Rs3.86 billion. The result was a Rs2.00 billion working-capital outflow during the nine-month period, including Rs1.14 billion absorbed by receivables and Rs477 million by inventory. Interim balance sheet and cash-flow statement.
That working-capital movement explains the apparent contradiction between profit and cash. Profit after tax was Rs883 million, but operations used Rs973 million of cash. The company also paid Rs801 million of dividends and added Rs557 million of short-term borrowing. Short-term borrowings consequently rose to Rs3.42 billion from Rs2.86 billion, while cash and short-term investments together fell sharply. Finance cost was Rs282 million for nine months. The economics are straightforward: if customers pay more slowly than Citi Pharma must pay suppliers, additional sales and inventory require bank funding, which then claims part of operating profit through interest. Interim cash-flow statement.
FY2025 tells the same story over a longer window. Receivables increased by Rs886 million and inventory by Rs726 million, helping turn Rs1.99 billion of pre-working-capital operating profit into negative Rs321 million of operating cash flow after finance cost and tax. Equity rose to Rs10.87 billion mainly because freehold land was revalued upward by Rs5.08 billion. That improves reported asset coverage but is not operating cash or retained earnings available for distribution. Audited cash-flow and equity statements.
Capital allocation, related interests and growth projects
The 2021 public offering funded API and formulation expansion. By FY2025, Rs555.2 million had been spent on API civil works and machinery and Rs557.6 million on formulation facilities. Shareholders subsequently approved reallocating Rs922.6 million originally earmarked for a hospital toward biotech ampoules, carbapenem and penicillin formulation projects. This changes the capital-allocation story from vertical diversification into hospital services toward deeper pharmaceutical manufacturing. It is strategically more adjacent to the existing operation, but execution still requires regulatory approvals, commissioning and working capital. IPO-proceeds note.
The accounts also contain related-party and non-core exposures that deserve monitoring. At June 2025 the company carried a Rs254.5 million long-term advance for shares of Yaqeen Developers Limited and Rs150.0 million of markup receivable from that related party; related markup income was Rs44.3 million for FY2025 and Rs24.7 million for the first nine months of FY2026. These amounts are disclosed and were considered recoverable by management, but they sit outside the core API-and-formulation cycle. Cash invested or receivable here should be assessed separately from pharmaceutical operating assets. Related-party and advance notes.
Competitive position, favourable conditions and risks
Citi Pharma’s structural advantage is local API manufacturing combined with a growing formulation platform. That can shorten supply chains for domestic manufacturers, reduce some imported-finished-input dependence and create internal demand for selected APIs. Its manufacturing base, product breadth, public-market access and established local sales provide a platform for additional products and exports. The limitation is concentration: although management discusses several product families, the accounts aggregate the business into one reportable segment and do not disclose molecule-level revenue, customer concentration or gross margin. Investors cannot independently see which APIs or formulations drive the improvement.
- Raw-material and currency risk: imported chemical inputs, freight and packaging can rise faster than regulated selling prices.
- Working-capital risk: receivables and inventory have been growing faster than sales, increasing reliance on short-term bank funding.
- Execution risk: biotech, penicillin, carbapenem and veterinary projects must pass regulatory, technical and commercial milestones.
- Product and quality risk: pharmaceutical manufacturing depends on batch consistency, testing, regulatory compliance and uninterrupted utilities.
- Customer and credit risk: more formulation sales can improve margin but may also require larger distributor inventories and longer credit.
- Non-operating allocation risk: related-party advances, investment income and asset revaluations can obscure the cash return from the core plant.
- Opportunity: a higher formulation mix, better yields and successful backward integration could raise gross margin and reduce external dependence.
- Opportunity: verified export registrations and commercial orders could diversify the overwhelmingly domestic FY2025 revenue base.
How to read this company’s results
Start with sales mix rather than sales alone. Track the API-versus-formulation percentage and calculate gross margin. A rising formulation share accompanied by a sustained margin gain supports management’s mix argument; a higher share without better margin may mean selling costs, discounts or production complexity are offsetting the benefit. Because the company reports one segment, the mix note is the best available window into the two economic engines.
Next, bridge operating profit to net profit. Review finance cost, other income, tax and any non-recurring items. FY2025 demonstrates why: operating profit grew by one-third, but net profit increased only 7% as other income declined and finance cost rose. Separate land revaluation from earnings and separate term-deposit or related-party markup from pharmaceutical operating profit.
Finally, reconcile profit to cash. Compare receivables, inventory, payables, operating cash flow, short-term borrowing and finance cost. For Citi Pharma, this is the decisive dashboard. A good result is not merely higher EPS; it is higher margin with receivables and inventory growing no faster than the business, positive operating cash flow and stable or falling short-term debt. Also check whether capital projects move from stated plans to commissioned assets, product registrations and commercial sales.
What to monitor next
The most useful indicators are: API and formulation revenue mix; gross margin; selling-expense growth; receivable and inventory days; operating cash flow; short-term borrowing and finance cost; export sales; new-product registrations; and verified commissioning of biotech, penicillin, carbapenem and veterinary facilities. The company’s official financial-report archive should be read alongside PSX disclosures because management’s project narrative can change before a new plant contributes earnings. Official financial-report archive.
AlphaGen inference: Citi Pharma’s strongest path is not simply selling more bulk API. It is using local API capability to support a larger, higher-value formulation portfolio while collecting cash fast enough to fund growth internally. The nine-month FY2026 margin expansion shows that this model can improve reported profitability. The negative operating cash flow shows that the model has not yet solved its funding burden. The next phase should therefore be judged on cash conversion and disciplined commissioning, not only on revenue, EPS or announced capacity.